AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04547816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tibial neuromodulation
Description: TNM is a standard procedure that is previously described as an effective method to treat functional insufficiency of the anal sphincter. It acts on the lumbosacral nerve plexus with an electric current through the posterior tibial nerve of one of the patient's limbs. For the study purpose a registered device for electric therapy (BioBravo, MTR Plus Vertriebs GmbH, Germany) is to be used.
Study NCT04547816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscles training
Description: PFMT is a complex of 5 exercises aimed to make functional training of pelvic floor muscles. This complex does not require additional equipment. It may be performed at home. The patients will be trained to perform this complex of exercises by a healthcare provider.~The complex of physical therapy consists of a single basic exercise for training coordinated muscle tension of abdominal wall and relaxation of the pelvic floor muscles, and 4 exercises to increase the contractility of pelvic floor muscles without additional involvement of the muscles of the abdominal wall. This allows to coordinate and consciously control the contraction and relaxation of the pelvic diaphragm. Initial course of training is 10 working days. Than patients continue the intervention for 6 months at home with online monitoring of the correctness and regularity of training.
Study NCT04547816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: Diet modification play an important role in the regulation of colonic transit and defecation. Dietary factors may act through faecal bulk by additional stimulation of mechanoreceptors of the rectum. At the same time, adequate intake of vitamins (for example, B12) may improve electric conductivity of nerves and thus impact the tone of pelvic floor muscles. Among other factors known to affect functional state of pelvic floor muscles and colonic transit are dietary fibers, adequate intake of water, regular meal intake. For the study purposes, it is planned to provide standard recommendation based on the national recommended daily allowances according to patients' sex, age and physical activity level.
Study NCT02043977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol injectable emulsion
Study NCT05557864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Pallidal Deep Brain Stimulation
Study NCT01156519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Salivary Cortisol
Description: * Day 1: 1st salivary cortisol at 23 hours~* Day 2: 2nd salivary cortisol at 23 hours and administration of dexamethasone (for overnight 1-mg dexamethasone suppression test)~* Day 3: serum cortisol at 8 am~* Between Day 4 and Month 3: if serum cortisol at 8 am > 18ng/mL:~* Cortisol for 24 hours~* dexamethasone suppression test (2mg/j during 2 days)~* Cortisol and ACTH cycle~* Noriodocholesterol scintigraphy
Study NCT03821129 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PFO closure with GORE® CARDIOFORM Septal Occluder
Description: PFO closure with GORE® CARDIOFORM Septal Occluder in patients with ischemic stroke
Study NCT01671397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and exercise counseling
Description: Not needed
Study NCT01671397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet, exercise, sleep hygiene counseling
Description: None needed
Study NCT01080716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 1/Arm 1 of Study: WRSS1 vaccine
Description: Single, oral dose of WRSS1
Study NCT01080716 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Part 1/Arm 2 of Study: Placebo vaccine
Description: Placebo vaccine
Study NCT01080716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 2/Arm 1 of Study: S. sonnei 53G
Description: Subject from Part 1/Arm 1 of Study are given 53G S. sonnei
Study NCT01080716 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Part 2/Arm 2 of Study: S. sonnei 53G
Description: 10 naïve controls are given S. sonnei 53G
Study NCT04315441 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: STEPS and AUDIT questionnaires
Description: assessment was done according to World Health Organization STEPS manual for surveillance of risk factors of Non-communicable chronic diseases; and the Alcohol Use Disorders Identification Test. Five cardiovascular risk factors were assessed, smoking, harmful alcohol consumption, obesity/overweight, hypertension and diabetes. Cardiovascular risk was considered high in subjects with three or more cardiovascular risk factors.
Study NCT01988207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal Hygiene Training
Description: Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
Study NCT01988207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocal Hygiene Training
Description: Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
Study NCT01988207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flow Phonation Exercises
Description: Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
Study NCT01988207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flow Phonation Exercises
Description: Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
Study NCT05461066 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CESAR training
Description: Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.
Study NCT05461066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CESAR training
Description: Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.
Study NCT02549014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1064
Description: Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)
Study NCT02549014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
Study NCT00564551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High dairy and calcium intake
Description: High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
Study NCT00564551 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual intake
Description: Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
Study NCT05598073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vinyasa yoga session
Description: One hour of vinyasa yoga will be completed.
Study NCT02443454 — intervention group
Intervention type: DEVICE
Intervention: Device: Complior Analyse System
Description: Monitoring of Arterial Stiffness and Central Aortic Pressure
Study NCT02443454 — intervention group
Intervention type: DEVICE
Intervention: Tanita BC 418- Bioelectrical impedance analysis
Description: The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
Study NCT01278173 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sabril
Description: Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
Study NCT02166294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEOX® CORD 1K
Description: Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
Study NCT02166294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (Pressure Bandage)
Description: Standard of Care wound, pressure dressing applied as needed at each visit.
Study NCT02166294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care (Pressure Bandage)
Description: Standard of Care wound, pressure dressing applied as needed at each visit.
Study NCT02685345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a 25 mg
Study NCT00619840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate hydrochloride
Description: sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
Study NCT00619840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
Study NCT03991871 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: External Counter Pulsation (ECP) therapy
Description: 35 hours ECP treatment in 35 sessions
Study NCT03991871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Counter Pulsation (ECP) therapy
Description: 35 hours ECP treatment in 35 sessions
Study NCT00288912 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: 12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.
Study NCT00288912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoarthritis Self-Management
Description: 12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
Study NCT02410759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 100 women with atonic PPH will receive Carbetocin 100 µgm IM
Study NCT02410759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergometrine
Description: 100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
Study NCT02254642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning during aortic clamping
Description: Ischemic preconditioning during aortic clamping
Study NCT02254642 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure/Surgery: usual surgery
Description: Procedure/Surgery: usual surgery
Study NCT03964948 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Kidney MRI
Description: An MRI examination will be completed per research MRI protocol.
Study NCT01749371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)
Study NCT02014272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIN 150
Description: Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
Study NCT02685345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg
Study NCT02685345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00672945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-03140
Study NCT00672945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02751320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.425 % w/w phytate,1150ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
Study NCT02751320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.85 % w/w phytate,1150ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
Study NCT02751320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
Study NCT02751320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0 ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
Study NCT02751320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1150ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
Study NCT02751320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
Study NCT03896412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detecton of circulating tumor DNA
Description: 7 blood samples to design a molecular probe
Study NCT00410982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Day -10 = 32 mg/m\^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m\^2 Intravenous
Study NCT00410982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Day -8 = 75 mg/m\^2 Intravenous bolus; Day -3 = 75 mg/m\^2 Intravenous bolus.
Study NCT00410982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Day -3 and Day -2 = 60 mg/m\^2 Intravenous.
Study NCT00410982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Infusion of stem cells on Day 0.
Study NCT00410982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab for Patients with B-Cell Malignancies
Description: 375 mg/m\^2 Intravenous on Days 1 and 8.
Study NCT00410982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
Study NCT00221026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen +ECP
Description: ECP + Uvadex given at weeks 1-12 weeks.
Study NCT00221026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: ECP given at weeks 1 through 12.
Study NCT02395146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: intraoperative EBSLN monitoring
Study NCT03093077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DePuy ATTUNE total knee arthroplasty system
Description: A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
Study NCT03093077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy ATTUNE total knee arthroplasty system
Description: A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
Study NCT00209716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 30 mg/m2, IV (in the vein) on day 1 of each 28 day cycle.
Study NCT00209716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 800 mg/m2, CIV (CIV.in the vein) on day 1\~5 of each 28 day cycle.
Study NCT00209716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Briplatin
Description: 15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle.
Study NCT00614965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
Study NCT00614965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
Study NCT00614965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
Study NCT02784249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goniotomy
Description: Procedure: Goniotomy and trabecular excision with a novel ophthalmic knife in combination with planned cataract extraction via Phaco and PCIOL implant.
Study NCT02784249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trabecular Micro-Bypass Stent
Description: Procedure: Trabecular Micro-Bypass stent implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
Study NCT02784249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Extraction
Description: Cataract extraction via Phaco and PCIOL implant.
Study NCT02784249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Extraction
Description: Cataract extraction via Phaco and PCIOL implant.
Study NCT04547283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No clinical team recommendation, patients will remain in their natural choice of position
Study NCT04547283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APPS
Description: Clinical team guidance on prone positioning of patients
Study NCT00866970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: ALD518 80 mg on Day 1, Week 8 and Week 16
Study NCT00866970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: ALD518 160 mg IV on Day 1, Week 8 and Week 16
Study NCT00866970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: ALD518 360 mg IV on Day 1, Week 8, and Week 16
Study NCT00866970 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of 0.9% Saline without ALD518
Description: Infusion of 0.9% Saline without addition of ALD518
Study NCT00759005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol and cortisol
Study NCT02835118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days
Study NCT02014272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reference drugs
Description: Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
Study NCT03281044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota capsules
Description: Patients will receive FMT capsules DE containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.
Study NCT03281044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
Study NCT02835118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two oral doses of placebo for surotomycin in hard gelatin capsules per day, for 14 days
Study NCT04554043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment
Study NCT00488397 — intervention group
Intervention type: OTHER
Intervention: In-vitro testing
Description: This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
Study NCT02491762 — intervention group
Intervention type: PROCEDURE
Intervention: respiratory function tests
Description: FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
Study NCT04040439 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine Hydrochloride
Description: \[Sedation during and after mechanical ventilation in the intensive care setting\] For pediatric patients ages of 6 years and over, dexmedetomidine is usually administrated by continuous intravenous (IV) infusion of at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.0 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition.~For pediatric patients with corrected gestational ages (gestational age + postnatal age) of 45 weeks to under 6 years, dexmedetomidine is usually administrated by continuous IV infusion at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.4 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition. The dosing rate could be decreased according to the patient's condition as appropriate.
Study NCT01170585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.